Published Date: 24 Apr 2023
Canada: The Journal of Psychiatric Research recently reported that childhood cat ownership, particularly with rodent-hunting cats,.
Read Full NewsHere's some of what is coming soon to NeurologyLive® this week.
Continuem's PIPE-307 trial for relapsing-remitting multiple sclerosis failed to meet primary goals, yet the company remains committed to exploring future therapies.
Gain Therapeutics advances Parkinson's treatment with GT 2287, showcasing promising safety and tolerability in ongoing trials. Discover the latest findings.
Daily Lemon Water Lowers Serum Urate Levels in Patients With Hyperuricemia
COPD in 2025: Year in Review
FDA Approves FUROSCIX On-Body Injector for Pediatric Patients, Accepts sNDA for ReadyFlow Autoinjector
Nephrology in 2025: Year in Review
1.
Prostate cancer screening seems to be improved by PSA, biomarker testing, and MRI combined.
2.
How Do Younger People Fare With Stool Tests for CRC Screening?
3.
Tumor characteristics found to differ for melanomas in children, teens and young adults
4.
Cardiomyocytes are shielded from chemotherapy damage by mitochondrial proteins.
5.
Survey shows cancer anxiety has impact well beyond the individual diagnosed
1.
Cancer Vaccines In India: The Latest Hope In The Fight Against Disease
2.
Unleashing the Power of Immune Triads: A Novel Approach to Cancer Immunotherapy
3.
Asymptomatic Thrombocytopenia: Unraveling the Enigma of Low Platelet Counts Without Symptoms
4.
Beyond the Cure: The Emerging Role of Tissue-Agnostic Therapies in Palliative Oncology
5.
A Mural of Thrombus: Unlocking the Power of Art to Combat Cardiovascular Disease
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part XIV
2.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI
4.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part III
5.
An Intro to The Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies.
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation